Development and Validation of an Inflammatory Prognostic Index to Predict Outcomes in Advanced/Metastatic Urothelial Cancer Patients Receiving Immune Checkpoint Inhibitors.

Publication

Development and Validation of an Inflammatory Prognostic Index to Predict Outcomes in Advanced/Metastatic Urothelial Cancer Patients Receiving Immune Checkpoint Inhibitors.

Journal Paper/Review - Apr 11, 2024

Mokbel Sara, Baciarello Giuilia, Lavaud Pernelle, Omlin Aurelius, Calabrò Fabio, Cathomas Richard, Aeppli Stefanie, Parent Pauline, Giannatempo Patrizia, Koster Kira-Lee, Appel Naara, Gonnet Philippe, Angius Gesuino, Tsantoulis Petros, Arkenau Hendrick-Tobias, Cattrini Carlo, Messina Carlo, Zeghondy Jean, Morelli Cristina, Loriot Yohann, Formica Vincenzo, Patrikidou Anna

Citation

Mokbel S, Baciarello G, Lavaud P, Omlin A, Calabrò F, Cathomas R, Aeppli S, Parent P, Giannatempo P, Koster K, Appel N, Gonnet P, Angius G, Tsantoulis P, Arkenau H, Cattrini C, Messina C, Zeghondy J, Morelli C, Loriot Y, Formica V, Patrikidou A. Development and Validation of an Inflammatory Prognostic Index to Predict Outcomes in Advanced/Metastatic Urothelial Cancer Patients Receiving Immune Checkpoint Inhibitors. Cancers (Basel) 2024; 16

Type

Journal Paper/Review (English)

Journal

Cancers (Basel) 2024; 16

Publication Date

Apr 11, 2024

Issn Print

2072-6694

Brief description/objective

Immune checkpoint inhibitors (ICIs) improve overall survival (OS) in advanced/metastatic urothelial cancer (a/mUC) patients. Preliminary evidence suggests a prognostic role of inflammatory biomarkers in this setting. We aimed to develop a disease-specific prognostic inflammatory index for a/mUC patients on ICIs.